Industry news

Russian pharma manufacturers shipped the medicines worth 271 billion rubles

GMP News

In January-October 2017, Russian pharmaceutical manufacturers shipped from their warehouses the medicinal products worth 271 billion rubles (ex warehouse prices, including VAT).

Tax Policy Should Support the Biobased Economy

Paul Winter / BioTech Now

BIO’s Brent Erickson today published a new column in Biofuels Digest, arguing that Congress should include policies supporting renewable chemicals in its tax reform effort. If Congress’ goal is to revitalize the manufacturing sector, it should level the playing field for biobased manufacturing.

Moving Toward Direct-to-Patient Models

Agnes Shanley / BioPharm International

Clinical trials pose major manufacturing and distribution challenges, which have been magnified by the trend to outsource more operations. The success of any clinical trial demands strong adherence to GxPs--required good current practices in manufacturing, clinical, distribution, and documentation. The end goal, says Matthew Caponi, senior director of North American depot and production services at PAREXEL, is providing assurance that the rights, safety, and wellbeing of patients are protected, and that the results of the trial will be unbiased and credible. 

The Trump administration is taking on drug prices — but not drug companies

Carolyn Y. Johnson / The Washington Post

President Trump swept into office threatening to bring the hammer down on high drug prices, accusing pharmaceutical companies of “getting away with murder.” Over the past few weeks, his administration has tweaked how Medicare reimburses hospitals for certain drugs and sought feedback on a radical idea to pass prescription drug rebates directly to seniors. All of this could ultimately lower out-of-pocket drug prices for some. But there's one part of the health-care system so far being spared any real pain: the drug companies themselves.

Registration of medicines in EAEU will be performed online

GMP News

The Eurasian Economic Union (EAEU) is completing the development of a unified information system that will facilitate the registration of medicinal products by businesses in the common market and provide complete information about these drugs to consumers.

Kaluga Pharmaceutical Cluster received silver certificate of Cluster Excellence

GMP News

In the period of October 24 – 26, 2017, the Association of Kaluga Pharmaceutical Cluster passed the procedure of the on-site audit conducted by the experts of the European Secretariat for Cluster Analysis. The procedure included the evaluation of the cluster management system and core activities  using 30 indicators in accordance with the methodology of the European Cluster Excellence Initiative. The assessment score of the Association of Kaluga Pharmaceutical Cluster performance for more than 70% of these indicators have significantly exceeded the required values. 

After unexpected tie, Amsterdam wins ‘coin toss’ for new EMA HQ

Brittany Meiling / Endpoints News

Well, that was unexpected. The EU’s third and final vote on the new location of the European Medicine Agency tied between Milan and Amsterdam, with Amsterdam winning the proverbial coin toss tie-breaker (EU officials drew the city’s name out of a bowl).

With only 2 warnings in 2017, pharma's ad police hits historic low

Beth Snyder Bulik / FiercePharma

As the end of the year nears, the pharma industry can usually look back at FDA enforcement letters for insight into the agency's thinking and guidance on marketing communications. But this year, there’s not much to review.

Russian pharmaceutical market reaches 863 billion rubles in Q1-Q3

GMP News

According to AlphaRM, September 2017 ended with the growth in the retail segment and fall in the public segment of the pharmaceutical market compared both to the previous month (+11% and -21%, respectively) and the past year (+1% and -21%, respectively).

Russian pharmaceutical industry strives for new achievements

GMP News

Over the past 8 years, since the beginning of the active implementation of the “Pharma 2020” program, the right vector of development has been set and, today, the Russian pharmaceutical industry is the fastest growing sector in the country. In 2016, the Russian pharmaceutical companies were developing at a much more dynamic pace than their foreign counterparts. In that year, their revenues amounted to 314.5 billion rubles, that is 23.7% more than in 2015. At the same time, the volume of drugs imported to the Russian market increased by 8.1% over the year to reach 493.1 billion rubles.